Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Opdivo, Repatha and Lynparza likely among China’s 2018 blockbuster nods: report
Opdivo, Repatha and Lynparza likely among China’s 2018 blockbuster nods: report
Opdivo, Repatha and Lynparza likely among China’s 2018 blockbuster nods: report
Submitted by
admin
on January 5, 2018 - 10:28am
Source:
Fierce Pharma
News Tags:
China
Opdivo
Repatha
Lynparza
drug approvals
Bristol-Myers Squibb
Amgen
AstraZeneca
Eli Lilly
Gilead Sciences
Headline:
Opdivo, Repatha and Lynparza likely among China’s 2018 blockbuster nods: report
Do Not Allow Advertisers to Use My Personal information
